Dosimetric impact of rotational errors in trigeminal neuralgia radiosurgery using CyberKnife.

PURPOSE: Trigeminal neuralgia (TN) can be treated on the CyberKnife system using two different treatment delivery paths: the general-purpose full path corrects small rotations, while the dedicated trigeminal path improves dose fall-off but does not allow rotational corrections. The study evaluates the impact of uncorrected rotations on brainstem dose and the length of CN5 (denoted as Leff) covered by the prescription dose. METHODS AND MATERIALS: A proposed model estimates the delivered dose considering translational and rotational delivery errors for TN treatments on the CyberKnife system. The model is validated using radiochromic film measurements with and without rotational setup error for both paths. Leff and the brainstem dose is retrospectively assessed for 24 cases planned using the trigeminal path. For 15 cases, plans generated using both paths are compared for the target coverage and toxicity to the brainstem. RESULTS: In experimental validations, measured and estimated doses agree at 1%/1 mm level. For 24 cases, the treated Leff is 5.3 ± 1.7 mm, reduced from 5.9 ± 1.8 mm in the planned dose. Constraints for the brainstem are met in 23 cases for the treated dose but require frequent treatment interruption to maintain rotational corrections <0.5° using the trigeminal path. The treated length of CN5, and plan quality metrics are similar for the two paths, favoring the full path where rotations are corrected. CONCLUSIONS: We validated an analytical model that can provide patient-specific tolerances on rotations to meet plan objectives. Treatment using the full path can reduce treatment time and allow for rotational corrections.

4D Monte Carlo dose reconstructions using surface motion measurements.

PURPOSE: To investigate the feasibility of a 4D Monte Carlo based dose reconstruction method to study the dosimetric impact of respiratory motion using surface motion measurements for patients undergoing VMAT treatments for Non-Small Cell Lung Cancer. METHODS: The 4Ddefdosxyznrc/EGSnrc algorithm was used to reconstruct VMAT doses delivered to the patients using machine log files and respiratory traces measured with the RADPOS 4D dosimetry system. The RADPOS sensor was adhered to the patient's abdomen prior to each treatment fraction and its position was used as a surrogate for tumour motion. Treatment log files were synchronized with the patient respiratory traces. Patient specific respiratory models were generated from deformable registration of the inhale and exhale 4DCT images and the respiratory traces. The reconstructed doses were compared to planned doses calculated with DOSXYZnrc/EGSnrc on the average-intensity and the exhale phase CT images. RESULTS: Respiratory motion measurements and log files were acquired for 2 patients over 5 treatment fractions each. The motion was predominantly along the anterior/posterior direction (A/P). The average respiratory amplitudes were 8.7 ± 2.7 mm and 10.0 ± 1.2 mm for Patient 1 and 2, respectively. Both patients displayed inter- and intra-fractional variations in the baseline position. Small inter-fractional differences were observed in the reconstructed doses for each patient. Differences between the reconstructed and planned doses were attributed to differences in organ volumes. CONCLUSION: The 4D reconstruction method was successfully implemented for the two patients studied. Small differences between the planned and reconstructed doses were observed due to the small tumour motion of these patients.

A dose perturbation tool for robotic radiosurgery: Experimental validation and application to liver lesions.

BACKGROUND: An analytical tool is empirically validated and used to assess the delivered dose to liver lesions accounting for different types of errors in robotic radiosurgery treatment. MATERIAL AND METHODS: A tool is proposed to estimate the target doses taking into account the translation, rotation, and deformation of a target. Translational errors are modeled as a spatial convolution of the planned dose with a probability distribution function derived from treatment data. Rotations are modeled by rotating the target volume about the imaging isocenter. Target deformation is simulated as an isotropic target expansion or contraction based on changes in inter-fiducial spacing. The estimated dose is validated using radiochromic film measurements in nine experimental conditions, including in-phase and out-of-phase internal-and-external breathing motion patterns, with and without uncorrectable rotations, and for homogenous and heterogeneous phantoms. The measured dose is compared to the perturbed and planned doses using gamma analyses. This proposed tool is applied to assess the dose coverage for liver treatments using D99/Rx where D99 and Rx are the minimum target and prescription doses, respectively. These metrics are used to evaluate plan robustness to different magnitudes of rotational errors. Case studies are presented to illustrate how to improve plan robustness against delivery errors. RESULTS: In the experimental validations, measured dose agrees with the estimated dose at the 2%/2 mm level. When accounting for translational and rotational tracking residual errors using this tool, approximately one-fifth of targets are considered underdosed (D99/Rx < 1.0). If target expansion or contraction is modeled, approximately one-third of targets are underdosed. The dose coverage can be improved if treatments are planned following proposed guidelines. CONCLUSION: The dose perturbation model can be used to assess dose delivery accuracy and investigate plan robustness to different types of errors.

Patient-specific PTV margins for liver stereotactic body radiation therapy determined using support vector classification with an early warning system for margin adaptation.

PURPOSE: An adaptive planning target volume (PTV) margin strategy incorporating a volumetric tracking error assessment after each fraction is proposed for robotic stereotactic body radiation therapy (SBRT) liver treatments. METHODS AND MATERIALS: A supervised machine learning algorithm employing retrospective data, which emulates a dry-run session prior to planning, is used to investigate if motion tracking errors are <2 mm, and consequently, planning target volume (PTV) margins can be reduced. A fraction of data collected during the beginning of a treatment course emulates a dry-run session (mock) before planning. Twenty features are calculated using mock data and used for support vector classification (SVC). A treatment course is labeled as Class 1 if the maximum root-mean-square radial tracking error for all remaining fractions is below 2 mm, or Class 2 otherwise. We evaluate the classification using fivefold cross-validation, leave-one-out cross-validation, 500 repeated random subsampling cross-validation, and the receiver operating characteristic (ROC) metric. The classification is independently cross-validated on a cohort of 48 treatment plans for other anatomical sites. A per fraction assessment of volumetric tracking errors is performed for the standard 5 mm PTV margin (PTVstd ) for courses predicted as Class 2; or for a margin reduced by 2 mm (PTVstd-2mm ) for those predicted as Class 1. We perturb the gross tumor volume (GTV) by the tracking errors for each x-ray image acquisition and calculate the fractional GTV voxel occupancy probability (Pi ) inside the PTV for each treatment fraction i. For treatment courses classified as Class 1, an early warning system flags treatment courses having any Pi  < 0.99, and the subsequent treatments are proposed to be replanned using PTVstd . RESULTS: The classification accuracies are 0.84 ± 0.06 using fivefold cross-validation, and 0.77 when validated using an independent testing set (other anatomical sites). Eighty percent of treatment courses are correctly classified using leave-one-out cross-validation. The sensitivity, precision, specificity, F1 score, and accuracy are 0.81 ± 0.09, 0.85 ± 0.08, 0.80 ± 0.11, 0.83 ± 0.06, and 0.80 ± 0.07, respectively, using 500 repeated random subsampling cross-validation. The area under the curve for the ROC metric is 0.87 ± 0.05. The four most important features for classification are related to standard deviations of motion tracking errors, the linearity between the target location and external LED marker positions, and marker radial motion amplitudes. Eleven of 64 cases predicted to be of Class 1 have 0.96 < Pi  < 0.99 for each treatment fraction, and require replanning using PTVstd . In comparison, the PTVstd always covers the perturbed GTVs with Pi  > 0.99 for all patients. CONCLUSIONS: Support vector classification is proposed for the classification of different motion tracking errors for patient courses based on a mock session before planning for SBRT liver treatments. It is feasible to implement patient-specific PTV margins in the clinic, assisted with an early warning system to flag treatment courses that require replanning using larger PTV margins in an adaptive treatment strategy.

Validation of 4D Monte Carlo dose calculations using a programmable deformable lung phantom.

PURPOSE: To validate the accuracy of 4D Monte Carlo (4DMC) simulations to calculate dose deliveries to a deforming anatomy in the presence of realistic respiratory motion traces. A previously developed deformable lung phantom comprising an elastic tumor was modified to enable programming of arbitrary motion profiles. 4D simulations of the dose delivered to the phantom were compared with the measurements. METHODS: The deformable lung phantom moving with irregular breathing patterns was irradiated using static and VMAT beam deliveries. Using the RADPOS 4D dosimetry system, point doses were measured inside and outside the tumor. Dose profiles were acquired using films along the motion path of the tumor (S-I). In addition to dose measurements, RADPOS was used to record the motion of the tumor during dose deliveries. Dose measurements were then compared against 4DMC simulations with EGSnrc/4DdefDOSXYZnrc using the recorded tumor motion. RESULTS: The agreements between dose profiles from measurements and simulations were determined to be within 2%/2 mm. Point dose agreements were within 2σ of experimental and/or positional/dose reading uncertainties. 4DMC simulations were shown to accurately predict the sensitivity of delivered dose to the starting phase of breathing motions. We have demonstrated that our 4DMC method, combined with RADPOS, can accurately simulate realistic dose deliveries to a deforming anatomy moving with realistic breathing traces. This 4DMC tool has the potential to be used as a quality assurance tool to verify treatments involving respiratory motion. Adaptive treatment delivery is another area that may benefit from the potential of this 4DMC tool.

AAPM TG 191: Clinical use of luminescent dosimeters: TLDs and OSLDs.

Thermoluminescent dosimeters (TLD) and optically stimulated luminescent dosimeters (OSLD) are practical, accurate, and precise tools for point dosimetry in medical physics applications. The charges of Task Group 191 were to detail the methodologies for practical and optimal luminescence dosimetry in a clinical setting. This includes: (a) to review the variety of TLD/OSLD materials available, including features and limitations of each; (b) to outline the optimal steps to achieve accurate and precise dosimetry with luminescent detectors and to evaluate the uncertainty induced when less rigorous procedures are used; (c) to develop consensus guidelines on the optimal use of luminescent dosimeters for clinical practice; and (d) to develop guidelines for special medically relevant uses of TLDs/OSLDs such as mixed photon/neutron field dosimetry, particle beam dosimetry, and skin dosimetry. While this report provides general guidelines for TLD and OSLD processes, the report provides specific details for TLD-100 and nanoDotTM dosimeters because of their prevalence in clinical practice.

Geometrical tracking accuracy and appropriate PTV margins for robotic radiosurgery of liver lesions by SBRT.

Purpose: To assess the geometrical accuracy and estimate adequate PTV margins for liver treatments using the Synchrony respiratory tracking system. Material and methods: Treatment log files are analyzed for 72 liver patients to assess tracking accuracy. The tracking error is calculated as the quadratic sum of the correlation, the predictor and the beam positioning errors. Treatment target rotations and rigid body errors reported by the system are also evaluated. The impact of uncorrected rotations is assessed by rotating the planned dose distribution and reassessing target coverage. Total PTV margins are estimated by summing in quadrature tracking errors and rigid body errors. Relationships are explored between tracking errors, model linearity and motion amplitudes of internal and external markers. Results: Margins of 3, 2, 2 mm in SUP-INF, LT-RT and ANT-POST directions, respectively, are sufficient to account for tracking and beam positioning errors for 95% of patients. If rigid body error is also considered, margins increase to 4 mm isotropic. Rotations could not be corrected for 92% of patients due to imperfect fiducial implantation and limitations in the magnitude of corrections that the system can apply. Uncorrected rotations would lead to average estimated dose reductions of 2.7% ± 5.8% of the prescribed dose for D99 of GTVs (5 mm PTV expansion) in which the target was well covered in the original plan (28 of 31 GTVs). 80% of tracking models exhibit near linear correlation between internal and external marker motions with small tracking errors (<2.2 mm). Conclusions: Isotropic PTV margins considering tracking errors and target rigid body errors could be used for liver SBRT treatments if rotational corrections can be calculated accurately so that systematic rotational offsets can be avoided. The linearity of the internal and external breathing motions might be useful for other types of treatment modalities for liver cancer.

Monte Carlo and analytic modeling of an Elekta Infinity linac with Agility MLC: Investigating the significance of accurate model parameters for small radiation fields.

PURPOSE: To explain the deviation observed between measured and Monaco calculated dose profiles for a small field (i.e., alternating open-closed MLC pattern). A Monte Carlo (MC) model of an Elekta Infinity linac with Agility MLC was created and validated against measurements. In addition, an analytic model which predicts the fluence at the isocenter plane was used to study the impact of multiple beam parameters on the accuracy of dose calculations for small fields. METHODS: A detailed MC model of a 6 MV Elekta Infinity linac with Agility MLC was created in EGSnrc/BEAMnrc and validated against measurements. An analytic model using primary and secondary virtual photon sources was created and benchmarked against the MC simulations and the impact of multiple beam parameters on the accuracy of the model for a small field was investigated. Both models were used to explain discrepancies observed between measured/EGSnrc simulated and Monaco calculated dose profiles for alternating open-closed MLC leaves. RESULTS: MC-simulated dose profiles (PDDs, cross- and in-line profiles, etc.) were found to be in very good agreements with measurements. The best fit for the leaf bank rotation was found to be 9 mrad to model the defocusing of Agility MLC. Moreover, a very good agreement was observed between results from the analytic model and MC simulations for a small field. Modifying the radial size of the incident electron beam in the BEAMnrc model improved the agreement between Monaco and EGSnrc calculated dose profiles by approximately 16% and 30% in the position of maxima and minima, respectively. CONCLUSION: Accurate modeling of the full-width-half-maximum (FWHM) of the primary photon source as well as the MLC leaf design (leaf bank rotation, etc.) is essential for accurate calculations of dose delivered by small radiation fields when using virtual source or MC models of the beam.

Evaluation of the 4D RADPOS dosimetry system for dose and position quality assurance of CyberKnife.

PURPOSE: The Synchrony respiratory motion tracking of the CyberKnife system purports to provide real-time tumor motion compensation during robotic radiosurgery. Such a complex delivery system requires thorough quality assurance. In this work, RADPOS applicability as a dose and position quality assurance tool for CyberKnife treatments is assessed quantitatively for different phantom types and breathing motions, which increase in complexity to more closely resemble clinical situations. METHODS: Two radiotherapy treatment experiments were performed where dose and position were measured with the RADPOS probe housed within a Solid Water phantom. For the first experiment, a Solid Water breast phantom was irradiated using isocentric beam delivery while stationary or moving sinusoidally in the anterior/posterior direction. For the second experiment, a phantom consisting of a Solid Water tumor in lung equivalent material was irradiated using isocentric and non-isocentric beam delivery while either stationary or moving. The phantom movement was either sinusoidal or based on a real patient's breathing waveform. For each experiment, RADPOS dose measurements were compared to EBT3 GafChromic film dose measurements and the CyberKnife treatment planning system's (TPS) Monte Carlo and ray-tracing dose calculation algorithms. RADPOS position measurements were compared to measurements made by the CyberKnife system and to the predicted breathing motion models used by the Synchrony respiratory motion compensation. RESULTS: For the static and dynamic (i.e., sinusoidal motion) cases of the breast experiment, RADPOS, film and the TPS agreed at the 2.0% level within 1.1 σ of estimated combined uncertainties. RADPOS position measurements were in good agreement with LED and fiducial position measurements, where the average standard deviation (SD) of the differences between any two of the three position datasets was ≤0.5 mm for all directions. For the 10 mm peak to peak amplitude sinusoidal motion of the breast experiment, the average Synchrony correlation errors were ≤0.2 mm, indicative of an accurate predictive model. For all the cases of the lung experiment, RADPOS and film measurements agreed with each other at the 2.0% level within 1.5 σ of estimated experimental uncertainties provided that the measurements were corrected for imaging dose. The measured dose for RADPOS and film were 4.0% and 3.4% higher, respectively, than the TPS for the most complex dynamic cases (i.e., irregular motion) considered for the lung experiment. Assessment of the Synchrony correlation models by RADPOS showed that model accuracy declined as motion complexity increased; the SD of the differences between RADPOS and model position data measurements was ≤0.8 mm for sinusoidal motion but increased to ≤2.6 mm for irregular patient waveform motion. These results agreed with the Synchrony correlation errors reported by the CyberKnife system. CONCLUSIONS: RADPOS is an accurate and precise QA tool for dose and position measurements for CyberKnife deliveries with respiratory motion compensation.

Development of a deformable phantom for experimental verification of 4D Monte Carlo simulations in a deforming anatomy.

PURPOSE: To verify the accuracy of 4D Monte Carlo (MC) simulations, using the 4DdefDOSXYZnrc user code, in a deforming anatomy. We developed a tissue-equivalent and reproducible deformable lung phantom and evaluated 4D simulations of delivered dose to the phantom by comparing calculations against measurements. METHODS: A novel deformable phantom consisting of flexible foam, emulating lung tissue, inside a Lucite external body was constructed. A removable plug, containing an elastic tumor that can hold film and other dosimeters, was inserted in the phantom. Point dose and position measurements were performed inside and outside the tumor using RADPOS 4D dosimetry system. The phantom was irradiated on an Elekta Infinity linac in both stationary and moving states. The dose delivery was simulated using delivery log files and the phantom motion recorded with RADPOS. RESULTS: Reproducibility of the phantom motion was determined to be within 1 mm. The phantom motion presented realistic features like hysteresis. MC calculations and measurements agreed within 2% at the center of tumor. Outside the tumor agreements were better than 5% which were within the positional/dose reading uncertainties at the measurement points. More than 94% of dose points from MC simulations agreed within 2%/2 mm compared to film measurements. CONCLUSION: The deformable lung phantom presented realistic and reproducible motion characteristics and its use for verification of 4D dose calculations was demonstrated. Our 4DMC method is capable of accurate calculations of the realistic dose delivered to a moving and deforming anatomy during static and dynamic beam delivery techniques.

Experimental verification of 4D Monte Carlo simulations of dose delivery to a moving anatomy.

PURPOSE: To evaluate a novel 4D Monte Carlo simulation tool by comparing calculations to physical measurements using a respiratory motion phantom. METHODS: We used a dynamic Quasar phantom in both stationary and breathing states (sinusoidal motion of amplitude of 1.8 cm and period of 3.3 s) for dose measurements on an Elekta Agility linear accelerator. Gafchromic EBT3 film and the RADPOS 4D dosimetry system were placed inside the lung insert of the phantom to measure dose profiles and point-dose values at the center of the spherical tumor inside the insert. Both a static 4 × 4 cm2 field and a VMAT plan were delivered. Static and 4D Monte Carlo simulations of the treatment deliveries were performed using DOSXYZnrc and a modified version of the defDOSXYZnrc user code that allows modeling of the continuous motion of both machine and patient. DICOM treatment plan files and linac delivery log files were used to generate corresponding input files. The phantom motion recorded by RADPOS during beam delivery was incorporated into the input files for the 4DdefDOSXYZnrc simulations. RESULTS: For stationary phantom simulations, all point-dose values from MC simulations at the tumor center agreed within 1% with film and within 2% with RADPOS. More than 98% of the voxels from simulated dose profiles passed a 1D gamma of 2%/2-mm criteria against measured dose profiles. Similar results were observed when applying a 2D gamma analysis with a 2%/2-mm criteria to compare 2D dose distributions of Monte Carlo simulations against measurements. For simulations on the moving phantom, MC-calculated dose values at the center of the tumor were found to be within 1% of film and within 2σ of experimental uncertainties which are 2.8% of the RADPOS measurements. 1D gamma comparisons of the dose profiles were better than 91%, and 2D gamma comparisons of the 2D dose distributions were found to be better than 94%. CONCLUSION: Our 4D Monte Carlo method using defDOSXYZnrc can be used to accurately calculate the dose distribution in continuously moving anatomy for various treatment techniques. This work, if extended to deformable anatomies, can be used to reconstruct patient delivered dose for use in adaptive radiation therapy.

Evaluation of a new commercial Monte Carlo dose calculation algorithm for electron beams.

PURPOSE: In this report the authors present the validation of a Monte Carlo dose calculation algorithm (XiO EMC from Elekta Software) for electron beams. METHODS: Calculated and measured dose distributions were compared for homogeneous water phantoms and for a 3D heterogeneous phantom meant to approximate the geometry of a trachea and spine. Comparisons of measurements and calculated data were performed using 2D and 3D gamma index dose comparison metrics. RESULTS: Measured outputs agree with calculated values within estimated uncertainties for standard and extended SSDs for open applicators, and for cutouts, with the exception of the 17 MeV electron beam at extended SSD for cutout sizes smaller than 5 × 5 cm(2). Good agreement was obtained between calculated and experimental depth dose curves and dose profiles (minimum number of measurements that pass a 2%/2 mm agreement 2D gamma index criteria for any applicator or energy was 97%). Dose calculations in a heterogeneous phantom agree with radiochromic film measurements (>98% of pixels pass a 3 dimensional 3%/2 mm γ-criteria) provided that the steep dose gradient in the depth direction is considered. CONCLUSIONS: Clinically acceptable agreement (at the 2%/2 mm level) between the measurements and calculated data for measurements in water are obtained for this dose calculation algorithm. Radiochromic film is a useful tool to evaluate the accuracy of electron MC treatment planning systems in heterogeneous media.

Real-time measurement of urethral dose and position during permanent seed implantation for prostate brachytherapy.

PURPOSE: The in vivo dosimetry tool, RADPOS, has been modified to include a metal oxide-silicon semiconductor field effect transistor (MOSFET) array with an electromagnetic positioning sensor. This allows dose monitoring at five points rather than just at single dose point as in the other versions of the device. The detector has been used in a clinical trial, which is the first to measure both urethral dose and internal motion concurrently during permanent seed implantation for prostate brachytherapy using a single probe. METHODS AND MATERIALS: The RADPOS detector was secured inside a Foley catheter inside the patient's urethra. Spatial coordinates of the RADPOS detector were read every 0.5s, and the timing of events such as needle insertion was noted. The MOSFET readings were taken over two 10-min periods; once all seeds had been implanted both before and after the transrectal ultrasound (TRUS), the probe was removed. Measurements were completed for 16 patients. RESULTS: Maximum integral dose in the prostatic urethral ranged from 89 to 195Gy, and dose varied from -66% to 36% depending on the rectal probe position. The change in position of the RADPOS sensor owing to the removal of the TRUS probe ranged from 1.4 to 9.7mm. CONCLUSIONS: The modified RADPOS detector with MOSFET array is able to provide real-time dose information, which can be used to monitor dose rates while implantation is performed and to estimate the total integrated dose. Changes in position including those owing to the TRUS probe can be significant and should be quantified to evaluate the influence on dose distributions.

In vivo dosimetry in brachytherapy.

In vivo dosimetry (IVD) has been used in brachytherapy (BT) for decades with a number of different detectors and measurement technologies. However, IVD in BT has been subject to certain difficulties and complexities, in particular due to challenges of the high-gradient BT dose distribution and the large range of dose and dose rate. Due to these challenges, the sensitivity and specificity toward error detection has been limited, and IVD has mainly been restricted to detection of gross errors. Given these factors, routine use of IVD is currently limited in many departments. Although the impact of potential errors may be detrimental since treatments are typically administered in large fractions and with high-gradient-dose-distributions, BT is usually delivered without independent verification of the treatment delivery. This Vision 20/20 paper encourages improvements within BT safety by developments of IVD into an effective method of independent treatment verification.

The effect of different bleaching wavelengths on the sensitivity of Al(2)O(3):C optically stimulated luminescence detectors (OSLDs) exposed to 6 MV photon beams.

PURPOSE: To determine the effect of different bleaching wavelengths on the response of Al(2)O(3):C optically stimulated luminescence detectors (OSLDs) exposed to accumulated doses of 6 MV photon beams. METHODS: In this study the authors used nanoDot OSLDs readout with a MicroStar reader. The authors first characterized the dose-response, fading, and OSL signal loss of OSLDs exposed to doses from 0.5 to 10 Gy. To determine the effect of different bleaching wavelengths on the OSLDs' response, the authors optically treated the OSLDs with 26 W fluorescent lamps in two modes: (i) directly under the lamps for 10, 120, and 600 min and (ii) with a long-pass filter for 55, 600, and 2000 min. Changes in the OSLDs' sensitivity were determined for an irradiation-readout-bleaching-readout cycle after irradiations with 1 and 10 Gy dose fractions. RESULTS: The OSLDs presented supralinearity for doses of 2 Gy and above. The signal loss rates for sequential readouts were (0.287 ± 0.007)% per readout in the reader's strong-stimulation mode, and (0.019 ± 0.002)% and (0.035 ± 0.007)% per readout for doses of 0.2 and 10 Gy, respectively, in the reader's weak-stimulation mode. Fading half-life values ranged from (0.98 ± 0.14) min to (1.77 ± 0.24) min and fading showed dose dependence for the first 10-min interval. For 10 and 55 min bleaching using modes (i) and (ii), the OSL signal increased 14% for an accumulated dose of 7 Gy (1 Gy fractions). For OSLDs exposed to 10 Gy fractions, the OSL signal increased 30% and 25% for bleaching modes (i) and (ii) and accumulated dose of 70 Gy, respectively. For 120 and 600 min bleaching using modes (i) and (ii), the OSL signal increased 2.7% and 1.5% for an accumulated dose of 7 Gy (1 Gy fractions), respectively. For 10 Gy fractions, the signal increased 14% for bleaching mode (i) (120 min bleaching) and decreased 1.3% for bleaching mode (ii) (600 min bleaching) for an accumulated dose of 70 Gy. For 600 and 2000 min bleaching using modes (i) and (ii), the signal increased 2.3% and 1.8% for an accumulated dose of 7 Gy (1 Gy fractions), respectively. For 10 Gy fractions, the signal increased 10% for mode (i) (600 min bleaching) and decreased 2.5% for mode (ii) (2000 min bleaching) for an accumulated dose of 70 Gy. CONCLUSIONS: The dose-response of nanoDot OSLDs read using the MicroStar reader presented supralinearity for doses of 2 Gy and above. The signal loss as a function of sequential readouts depended on dose. Fading also depended on dose for the first 10-min interval. For dose fractions of 1 and 10 Gy, OSLDs may be reused within 3% and 5% accuracies up to the maximum accumulated dose of 7 and 70 Gy investigated in this study, respectively. These accuracies were obtained after the OSLDs were bleached with a light source with wavelengths above about 495 nm. The authors also concluded that changes in sensitivity of OSLDs depended on bleaching time, accumulated dose, and wavelength spectrum of the bleaching source.

Clinical use of a novel in vivo 4D monitoring system for simultaneous patient motion and dose measurements.

PURPOSE: A new 4D in vivo dosimetry tool, RADPOS, has been used on lung cancer patients to evaluate the feasibility of using the detectors to characterize variations in patient breathing patterns as well as to monitor daily variations in dose. METHODS AND MATERIALS: The RADPOS system combines a MOSFET dosimeter with an electromagnetic positioning sensor for simultaneous measurement of real-time dose and spatial coordinates. Three RADPOS sensors were placed on patients' chest and abdomen during a 4DCT and daily treatments. A fourth detector was also placed on the couch as reference. Position data were collected in real-time and total dose was read at the end of each fraction. RESULTS: Significant deviations in surface motion have been found between the day of 4DCT and treatment fractions in 9 of 10 patients. Variations in daily dose ranged from 2.5 to 13.7 cGy (2.8-14.0%) and results agreed with treatment plan values for all but three points. CONCLUSIONS: Changes in breathing motion have been found that emphasize a need for continued position monitoring. RADPOS measurements can be used to monitor such variations as well as to measure surface dose without any disruption to the treatment schedule or discomfort to patients.

4D dose-position verification in radiation therapy using the RADPOS system in a deformable lung phantom.

PURPOSE: A novel 4D in vivo dosimetry system (RADPOS), in conjunction with a deformable lung phantom, has been evaluated as a potential quality assurance tool for 4D radiotherapy. METHODS: RADPOS detectors, which consist of a MOSFET dosimeter combined with an electromagnetic positioning probe, were placed inside the deformable lung phantom. One detector was positioned directly inside a tumor embedded in the lung phantom and another was positioned inside the lung portion of the phantom, outside the tumor. CT scans were taken with the phantom at three breathing phases, and for each phase, the detector position inside the phantom was read with the RADPOS software and compared to the position as determined from the CT data. These values were also compared to RADPOS measurements taken with the phantom on the couch of a Varian Clinac 6EX linac. The deformable phantom and the RADPOS system were also used in two radiation delivery scenarios: (1) A simulation of a free-breathing delivery and (2) a simulation of an adaptive treatment. RESULTS: Compared to CT imaging, the RADPOS positional accuracy was found to be better than 2.5 mm. The radial displacement measurements taken in the CT and linac rooms agreed to within an average of (0.7 +/- 0.3) mm. Hence, the system can provide relative displacement measurements in the treatment room, consistent with measurements made in the CT room. For the free-breathing delivery, the total dose reported by RADPOS agreed to within 4% and 5% of the treatment planning doses in the tumor and the lung portion of the phantom, respectively. The RADPOS-measured dose values for the adaptive delivery were within 1.5% of the treatment plan values, which was well within the estimated experimental uncertainties. CONCLUSIONS: This work has shown that the deformable lung phantom-RADPOS system can be an efficient quality assurance tool for 4D radiation therapy.

Penile brachytherapy: technical aspects and postimplant issues.

PURPOSE: Squamous carcinoma (SCC) of the penis affects about 1 in 100,000 men in western societies. Interstitial brachytherapy can be an effective penis-conserving modality for T1, T2, and selected T3 tumors. Unfortunately, few radiation oncology trainees have the opportunity to treat a case of penile cancer during their residency, and few centers have brachytherapy expertise for this tumor site. We report our technique that has been developed and refined over the past 20 years. MATERIALS AND METHODS: From 1989 to 2009, we have been using brachytherapy to treat penile SCC and have experience with 75 cases. From 1989 to 1998, manual afterloading was used with (192)Ir wire or seeds, and from 1999 to the present, pulse dose rate automated afterloading. Sixty Gray is delivered over a period of 4-5 days. RESULTS: Patient selection for penile brachytherapy and the technical and dosimetric aspects of the procedure will be discussed along with posttreatment care and followup. CONCLUSIONS: Brachytherapy is an effective treatment for T1, T2, and selected T3 SCC of the penis. Efficacy depends on careful planning and appreciation of dosimetry.

MOSFET detectors in quality assurance of tomotherapy treatments.

BACKGROUND AND PURPOSE: The purpose of this work was to characterize metal oxide semiconductor field-effect transistors (MOSFETs) in a 6 MV conventional linac and investigate their use for quality assurance of radiotherapy treatments with a tomotherapy Hi-Art unit. MATERIALS AND METHODS: High sensitivity and standard sensitivity MOSFETs were first calibrated and then tested for reproducibility, field size dependence, and accuracy of measuring surface dose in a 6 MV beam as well as in a tomotherapy Hi-Art unit. In vivo measurements were performed on both a RANDO phantom and several head and neck cancer patients treated with tomotherapy and compared to TLD measurements and treatment plan doses to evaluate the performance of MOSFETs in a high gradient radiation field. RESULTS: The average calibration factor found was 0.345+/-2.5%cGy/mV for the high sensitivity MOSFETs tested and 0.901+/-2.4%cGy/mV for the standard sensitivity MOSFETs. MOSFET measured surface doses had an average agreement with ion chamber measurements of 1.55% for the high sensitivity MOSFET and 5.23% for the standard sensitivity MOSFET when averaged over all trials and field sizes tested. No significant dependence on field size was found for the standard sensitivity MOSFETs, however a maximum difference of 5.34% was found for the high sensitivity MOSFET calibration factors in the field sizes tested. Measurements made with MOSFETS on head and neck patients treated on a tomotherapy Hi-Art unit had an average agreement of (3.26+/-0.03)% with TLD measurements, however the average of the absolute difference between the MOSFET measurements and the treatment plan skin doses was (12.2+/-7.5)%. The MOSFET measured patient skin doses also had good reproducibility, with inter-fraction deviations ranging from 1.4% to 6.6%. Similar results were found from trials using a RANDO phantom. CONCLUSIONS: The MOSFETs performed well when used in the tomotherapy Hi-Art unit and did not increase the overall treatment set-up time when used for patient measurements. It was found that MOSFETs are suitable detectors for surface dose measurements in both conventional beam and tomotherapy treatments and they can provide valuable skin dose information in areas where the treatment planning system may not be accurate.

Report of the AAPM Task Group No. 105: Issues associated with clinical implementation of Monte Carlo-based photon and electron external beam treatment planning.

The Monte Carlo (MC) method has been shown through many research studies to calculate accurate dose distributions for clinical radiotherapy, particularly in heterogeneous patient tissues where the effects of electron transport cannot be accurately handled with conventional, deterministic dose algorithms. Despite its proven accuracy and the potential for improved dose distributions to influence treatment outcomes, the long calculation times previously associated with MC simulation rendered this method impractical for routine clinical treatment planning. However, the development of faster codes optimized for radiotherapy calculations and improvements in computer processor technology have substantially reduced calculation times to, in some instances, within minutes on a single processor. These advances have motivated several major treatment planning system vendors to embark upon the path of MC techniques. Several commercial vendors have already released or are currently in the process of releasing MC algorithms for photon and/or electron beam treatment planning. Consequently, the accessibility and use of MC treatment planning algorithms may well become widespread in the radiotherapy community. With MC simulation, dose is computed stochastically using first principles; this method is therefore quite different from conventional dose algorithms. Issues such as statistical uncertainties, the use of variance reduction techniques, the ability to account for geometric details in the accelerator treatment head simulation, and other features, are all unique components of a MC treatment planning algorithm. Successful implementation by the clinical physicist of such a system will require an understanding of the basic principles of MC techniques. The purpose of this report, while providing education and review on the use of MC simulation in radiotherapy planning, is to set out, for both users and developers, the salient issues associated with clinical implementation and experimental verification of MC dose algorithms. As the MC method is an emerging technology, this report is not meant to be prescriptive. Rather, it is intended as a preliminary report to review the tenets of the MC method and to provide the framework upon which to build a comprehensive program for commissioning and routine quality assurance of MC-based treatment planning systems.